Deisseroth. Albert. B. 
FF 
Princip al Investigator/Program DixectQT{Last first , middle ) . — 
BIOGRAPHICAL SKETCH 
Give the following information for the key personnel and consultants and collaborators. Begin with the principal 
investigator/program director. Photocopy this page for each person. 
name 
Albert B. Deisseroth, M.D., Ph.D. 
POSITION TITLE 
Professor and Chairman 
EDUCATION (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION 
DEGREE 
YEAR 
CONFERRED 
FIELD OF STUDY 
Univ. of Rochester, Rochester, NY 
A.B. 
1963 
Chemistry 
Univ. of Rochester School of Medicine, NY 
Ph.D. 
1968 
Biochemistry 
Univ. of Rochester School of Medicine, NY 
M.D. 
1970 
Medicine 
Intern Sc Junior Resident, Beth Israel Hospital, MA 
Resident 
1970-1972 
Internal Medicine 
Sidney Farber Center 
Fellow 
1975-1976 
Hematology/ Oncology 
RESEARCH AND PROFESSIONAL EXPERIENCE: Concluding with present position, list, in chronological order, previous employment, 
experience, and honors. Key personnel include the principal investigator and any other individuals who participate in the scientific 
development or execution of the project. Key personnel typically will include all individuals with doctoral or other professional degrees, 
but in some projects will include individuals at the masters or baccalaureate level provided they contribute in a substantive way to the 
scientific development or execution of the project. Include present membership on any Federal Government public advisory co mmi ttee. 
List, in chronological order, the titles, all authors, and complete references to all publications during the past three years and to 
representative earlier publications pertinent to this application. DO NOT EXCEED TWO PAGES. 
POSITIONS HELD 
1970 - 1972 
1972 - 1974 
10- * . 1975 
1 1976 
1976 - 1981 
1981 - 1987 
1987 - present 
1987 - present 
Intern and Resident, Beth Israel Hospital, Boston, MA 
Clinical Associate, NHLI, NTH 
Chief Resident Physican, NHLI, NIH 
Clinical Fellow, Hematology /Oncology, Children’s Hospital Medical Center, Boston, MA 
Head, Experimental Hematology Section, Pediatric Oncology Branch, NCI, NIH 
Chief, Hematology/Oncology Section, Department of Medicine, UCSF Service, San Francisco VA Medical 
Center, and Professor of Medicine, UCSF 
Prof, of Medicine and Chairman, Dept, of Hematology, U.T. M.D. Anderson Cancer Center, Houston, TX 
Anderson Professor of Cancer Treatment and Research, M.D. Anderson Cancer Center, Houston, TX 
RELEVANT PUBLICATIONS : (Selected from 180 publications) 
1 . Abrams R, McCormack K, Bowles C, and Deisseroth A: Cyclophosphamide treatment expands the circulating hematopoietic stem 
cell pool in dogs. J Clin Invest 67:1379-1399, 1981. 
2. Wright DG, Robichaud KJ, Pizzo PA, and Deisseroth AB: Lethal p ulm onary reactions associated with the combined use of 
amphotericin B and transfusions. N Engl J Med 304:1185-1189, 1981. 
3. Anagnou NP, Lim E, Yuan TY, Helder J, Wieder S, Marks B, Wang A, Colbert D, and Deisseroth A: Trans acting regulatory 
factors in mouse erythroleukemia cells are specific for adult globin genes. Blood 65:707-712, 1986. 
4. Lopez A, Barker J, and Deisseroth A: V-Abl activates embryonic globin gene expression. Proc Natl Acad Sci USA 83:2042-2046, 
1986. 
5. Helder J and Deisseroth A: Acquired hemoglobin H and leukemia. Proc Natl Acad Sci USA 84:2387-2390, 1987. 
6. Howard OMZ, Kane C, Deisseroth A: 5’ region of zeta globin and GMCSF genes share binding site for nuclear proteins. 
Transactions of the Association of American Physicians Vol Cl: 180-184, 1988. 
7. Spitzer G, Deisseroth A, Ventura G, Jagannath S, Fogel B, Taylor K, Huan S, Dunphy F, Dicke K, Sonza L, Yau J, LeMaistre 
F, Spinolo J: Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate 
the neutropenic trough of high dose therapy. Inti J Cell Cloning . 1990 (in press). 
8. LeMaistre A, Lee MS, Talpaz M, Kantaijian H, Deisseroth A, Freireich E, Trujillo J, and Stass S: Ras oncogene mutations are 
rare late stage events in chronic myelogenous leukemia. Blood 23:889-891, 1989. 
9. Gandara DR, Wold H, Perez EA, Deisseroth AB, Doroshow J, Meyers F, McWhirter K. Hannigan J DeGregorio MW: Cisplatin 
dose intensity in nonsmall cell lung cancer: Phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 81:790- 
794, 1989. 
10. Mashal R, Shtalrid M, Talpaz M, Kantaijian H, Smith L, Beran M, Gutterman J, and Deisseroth A: Rearrangement and 
expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 75:180-189, 199° 
PHS [412] 
Numbu. r - 0 
FF 
Recombinant DNA Research, Volume 16 
